- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03680287
Effects of Sleep Disruption on Drug Response
The central scientific premise of the proposed study is that sleep disruption (SD) will influence individuals' subjective response to blinded medication administration. The investigators further believe these responses will vary among patients who have chronic low back pain (CLBP) vs. healthy controls, and that sex will moderate effects.
The proposed study evaluates whether CLBP patients' subjective responses to study medication administration are altered by SD. The investigators focus on two outcome domains: abuse liability (i.e., drug liking and valuation) and response to pain testing.
The investigators propose a mixed between-within randomized crossover human-laboratory experiment that investigates placebo-controlled effects of study medication on 1) abuse liability metrics (Drug Liking and Monetary Valuation) and 2) response to laboratory-evoked standardized pain measures, after one night of uninterrupted sleep (US) and again after one night of SD. The investigators will recruit both CLBP patients(*) and healthy controls (N = 60).
(*) We originally aimed to accrue 60 subjects with CLBP. However, we have been granted approval by the National Institute on Drug Abuse (NIDA) to reduce expectations for the target N for the CLBP cohort. We are no longer expected to recruit N=60 CLBP participants; this is a COVID-19 modification, and we are not required to re-do a power analysis.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Michael T. Smith, PhD
- Phone Number: 410-550-9059
- Email: msmith62@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Recruiting
- Johns Hopkins School of Medicine
-
Contact:
- Michael T Smith, Ph.D.
- Phone Number: 410-550-9059
- Email: msmith62@jhmi.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
General Inclusion Criteria:
- 18-60 years old
- Less than 2 servings/day of caffeinated beverages and willing to discontinue 3 days prior to admission.
CLBP-Specific Inclusion Criteria:
- Have a physician-confirmed diagnosis of CLBP
- Report chronic low back pain.
Exclusion Criteria:
General Exclusion Criteria:
- BMI >40
- Significant medical or psychiatric morbidity within 6 months or lifetime history of bipolar disorder, psychotic disorder, seizure disorder
- Lifetime history of opioid use disorder
- Clinically significant abnormal complete blood count or comprehensive metabolic profile
- Any contraindicated medical condition (status asthmaticus; chronic obstructive pulmonary disease; reduced respiratory function; hypotension; hypertension; impairment of hepatic, pulmonary or renal functions; myxedema or hyperthyroidism; adrenocortical insufficiency; gastrointestinal obstruction; gall bladder disease; acute alcoholism; history of convulsive disorders; history of head injury)
- Current use of stimulants, opioids, benzodiazepines or other Central Nervous System (CNS) depressant
- Positive toxicology screen for opioids, stimulants, or recreational drugs
- Pregnancy or lactation
- Significant preadmission psychological distress.
Healthy Control and CLBP-Specific Exclusion Criteria:
- Report current medical/psychiatry history
- Report acute painful injury (within 3 months)
- Have a diagnosed chronic pain disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Uninterrupted Sleep
Participants will be permitted to sleep without interruption for 8 hours.
|
On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo.
This is a double-blind within-subject Phase II trial.
As such, study medications must remain blinded.
Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline).
This study uses a within-subject design, such that participants serve as participants' own control.
|
Experimental: Sleep Disruption
Participants will be repeatedly awakened throughout the night according to a standardized protocol.
|
On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo.
This is a double-blind within-subject Phase II trial.
As such, study medications must remain blinded.
Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline).
This study uses a within-subject design, such that participants serve as participants' own control.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug Liking as assessed by the Visual Analog Scale
Time Frame: up to 420 minute post-medication administration
|
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Do you like the drug?"
|
up to 420 minute post-medication administration
|
Heat Pain Threshold
Time Frame: up to 420 minute post-medication administration
|
A thermode will gradually increase in temperature until the participant indicates when it "first feels painful".
The outcome will be the temperature (degrees Celsius) at which the participant indicates they first feel pain.
|
up to 420 minute post-medication administration
|
Suprathreshold Tonic Heat Pain
Time Frame: up to 420 minute post-medication administration
|
A painful temperature above threshold will be held tonically for a period of time, after which pain ratings are obtained on a 0-100 numerical rating scale, where 0 = "No Pain" and 100 = "Worst Pain Imaginable."
|
up to 420 minute post-medication administration
|
Monetary Valuation of Drug as assessed by the Drug vs. Money Multiple Choice Questionnaire
Time Frame: up to 420 minute post-medication administration
|
Participants are presented with an array of choices (in dollar value) which they will compare to the option of receiving study drug.
They will decide for each choice whether they would take the money (at that value) or the drug they received in the session.
The outcome will be the "crossover point", which is the mean of the last price that the participant selected "drug" and the first price at which the participant selected "money".
|
up to 420 minute post-medication administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Good Drug Effects as assessed by the Visual Analog Scale
Time Frame: up to 420 minute post-medication administration
|
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does the drug have any good effects?"
|
up to 420 minute post-medication administration
|
Bad Drug Effects as assessed by the Visual Analog Scale
Time Frame: up to 420 minute post-medication administration
|
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does the drug have any bad effects?"
|
up to 420 minute post-medication administration
|
Level of "Highness" as assessed by Visual Analog Scale
Time Frame: up to 420 minute post-medication administration
|
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "How high are you?"
|
up to 420 minute post-medication administration
|
Feeling of Sickness as assessed by Visual Analog Scale
Time Frame: up to 420 minute post-medication administration
|
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does this drug make you feel sick?"
|
up to 420 minute post-medication administration
|
Clinical Pain
Time Frame: up to 420 minute post-medication administration
|
This will be rated on a 0-100 Numerical Rating Scale, where 0 = "No Pain" and 100 = "Worst Pain Imaginable."
|
up to 420 minute post-medication administration
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael T. Smith, PhD, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00160629
- R01DA048206 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Within-Subject test of blinded study medication
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid Sensitivity | Individual Difference | Abuse OpioidsUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Johns Hopkins UniversityCompletedPain | Cannabis | Opioid Use, UnspecifiedUnited States
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingHealthy | Sleep DisorderUnited States
-
BioMérieuxTerminatedSepsis | Septic Shock | Acute Kidney InjuryUnited States, Belgium, France, Germany
-
National Jewish HealthNational Institute on Drug Abuse (NIDA)Active, not recruitingHypnotic Dependence Among Those With InsomniaUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Emory UniversityDexCom, Inc.Recruiting
-
Chang Gung Memorial HospitalCompleted
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...CompletedRenal Cell CarcinomaChina